Sandhill Capital Partners’s Matinas BioPharma MTNB Stock Holding History

Sandhill Capital Partners’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$40K	–	97
2022 Q1	$40K	Hold	1,000	–	–	﹤0.01%	86
2021 Q4	$50K	Sell	1,000 -400	-29%	-$21.4K	﹤0.01%	85
2021 Q3	$91K	Buy	1,400 +800	+133%	+$34.5K	0.01%	89
2021 Q2	$23K	Buy	600 +200	+50%	+$8.6K	﹤0.01%	86
2021 Q1	$21K	Buy	400 +200	+100%	+$13.4K	﹤0.01%	81
2020 Q4	$14K	Buy	+200	New	+$9.26K	﹤0.01%	82

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Sandhill Capital Partners's MTNB Position: Q2 2022 in Review

Sandhill Capital Partners sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 1,000 shares — an estimated $40K sold.

Sandhill Capital Partners first reported a position in MTNB in Q4 2020 and held it in 6 quarters. The position peaked at $91K in Q3 2021. 50 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

Sandhill Capital Partners reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
Sandhill Capital Partners sold 1,000 Matinas BioPharma shares in Q2 2022, an estimated $40K.
Sandhill Capital Partners first reported a position in Matinas BioPharma in Q4 2020 and held it in 6 quarters.
Sandhill Capital Partners's Matinas BioPharma position peaked at $91K in Q3 2021.
50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Sandhill Capital Partners's 13F filing for Q2 2022, filed 10 Aug 2022.